EP
PCRX icon

Eversept Partners’s Pacira BioSciences PCRX Stock Holding History

Eversept Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-132,655
Closed -$6.96M – 61
2020
Q2 		$6.96M Buy
+132,655
New +$5.54M 0.95% 27
2018
Q1 		– Sell
-25,100
Closed -$1.15M – 60
2017
Q4 		$1.15M Buy
+25,100
New +$995K 0.66% 29

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eversept Partners's PCRX Position: Q3 2020 in Review

Eversept Partners sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 132,655 shares — an estimated $6.96M sold.

Eversept Partners first reported a position in PCRX in Q4 2017 and held it in 2 quarters. The position peaked at $6.96M in Q2 2020. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Eversept Partners reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Eversept Partners sold 132,655 Pacira BioSciences shares in Q3 2020, an estimated $6.96M.
  • Eversept Partners first reported a position in Pacira BioSciences in Q4 2017 and held it in 2 quarters.
  • Eversept Partners's Pacira BioSciences position peaked at $6.96M in Q2 2020.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.